Special Issue

New Developments in Polio Vaccine

Message from the Guest Editor

The discovery of two vaccines against poliomyelitis—first the inactivated poliovirus vaccine (IPV) created by Jonas Salk, and soon after the live oral poliovirus vaccine (OPV) by Albert Sabin—was an enormous medical breakthrough of the mid-20th century. Their creation and use established a paradigm for other vaccines. OPV was so successful that in 1988, the World Health Assembly resolved to completely eradicate poliomyelitis by the year 2000. Even though the deadline was not met and polio eradication remains a moving target 35 years later, the Global Polio Eradication Initiative achieved tremendous progress. It also became clear that the current versions of IPV and OPV are not optimal for a post-eradication world. IPV is made from highly virulent virus strains and does not prevent virus transmission. OPV causes rare but serious adverse events and can trigger new outbreaks caused by a vaccine-derived virus. Therefore, finishing the eradication campaign and making its success irreversible requires the development and introduction of a new generation of polio vaccines. This Special Issue is devoted to these ongoing efforts.

Guest Editor

Dr. Konstantin Chumakov

Division of Viral Products, Center for Biologics Evaluation and Research, US Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD 20993, USA

Deadline for manuscript submissions

closed (20 June 2024)

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/si/187930

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/journal/vaccines

About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp
Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).

MDPI